Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report

Wu,Lu; Li,Mei; Liu,Dingyi; Jiang,Ming; Liu,Yanyang; Li,Zhixi; Wang,Xia; Yu,Yang; Luo,Feng

doi:10.3892/ol.2014.2180

Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report

Authors:
- Lu Wu
- Mei Li
- Dingyi Liu
- Ming Jiang
- Yanyang Liu
- Zhixi Li
- Xia Wang
- Yang Yu
- Feng Luo
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Oncology, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610041, P.R. China
Published online on: May 26, 2014 https://doi.org/10.3892/ol.2014.2180
Pages: 753-757

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In China, the incidence of nasopharyngeal carcinoma (NPC) and tuberculosis remains high. Additionally, there has been a marked increase in the prevalence of gout. In recent years, there has been an increase in the number of co‑existing diseases. To the best of our knowledge, there have been no previous cases reported in the literature with regard to patients suffering from NPC complicated with pulmonary tuberculosis and gout. The present study describes the case of a 59‑year‑old male with this condition. The patient received a combination of anti‑tumor, anti‑tuberculosis and anti‑gout therapies, and experienced no severe adverse reactions during treatment. At present, the patient's Eastern Cooperative Oncology Group performance status is good, there has been no local recurrence or distant metastasis of the NPC, and the pulmonary tuberculosis and gout are well controlled. The aim of this study was to provide insight into the treatment of patients suffering from co‑existing conditions.

View Figures

View References

1	Trejaut J, Lee CL, Yen JC, Loo JH and Lin M: Ancient migration routes of Austronesian-speaking populations in oceanic Southeast Asia and Melanesia might mimic the spread of nasopharyngeal carcinoma. Chin J Cancer. 30:96–105. 2011.
2	Wee JT, Ha TC, Loong SL and Qian CN: Is nasopharyngeal carcinoma really a ‘Cantonese Cancer’? Chin J Cancer. 29:517–526. 2010.
3	He GX, van denHof S, van der Werf MJ, et al: Infection control and the burden of tuberculosis infection and disease in health care workers in china: a cross-sectional study. BMC Infect Dis. 10:3132010.
4	Sun GM, Gao Q and Peng WX: Progress on spatial epidemiology of tuberculosis. Zhonghua Liu Xing Bing Xue Za Zhi. 31:1188–1191. 2010.(In Chinese).
5	Miao Z, Li C, Chen Y, et al: Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 35:1859–1864. 2008.
6	Li R, Sun J, Ren LM, et al: Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 51:721–729. 2012.
7	Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 16:1310–1317. 1998.
8	Komatsu M, Tsukuda M, Matsuda H, et al: Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma. Anticancer Res. 32:681–686. 2012.
9	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. http://www.nccn.org/93c288ea1c3664690434dfff86acacfe/head-and-neck.pdf. Accessed April 28, 2014
10	Lee NY, Zhang Q, Pfister DG, et al: Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 13:172–180. 2012.
11	Lu T, Zhao C, Chen C, et al: An open, muticenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): A 2-year follow-up report. In: 2012; ASCO Annual Meeting; J Clin Oncol. 30(suppl): pp. abstr 55352012
12	Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E and Nair P: Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther. 10:673–681. 2010.
13	Rodríguez MO, Rivero TC, del Castillo Bahi R, et al: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 9:343–349. 2010.
14	Huang XD, Yi JL, Gao L, et al: Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for Iocoregionally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi. 29:197–201. 2007.
15	Huncharek M and Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 25:219–223. 2002.
16	Thephamongkhol K, Zhou J, Browman G, et al: Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. In: 2004; ASCO Annual Meeting; J Clin Oncol. 22(suppl 14): pp. abstr 55222004
17	Shao-jun C, Hai-xin H and Gui-sheng L: Different dosage cisplatin based concurrent radiochemotherapy in the treatment for locally advanced nasopharyngeal carcinoma. Zhong Guo Zhong Liu. 18:597–599. 2009.(In Chinese).
18	Dong-ning H, Hai-xin H and Shao-jun C: Different administration regimens of cisplatin combined with concurrent radiotherapy for 65 cases with locally advanced nasopharyngeal carcinoma. Zhong Liu Xue Za Zhi. 15:836–838. 2009.(In Chinese).
19	Shi W, Zhou Q and Ju W: Observation on therapeutic effects of chemotherapy involving oxaliplatin in treatment of advanced nasopharyngeal carcinoma. Zhong Guo Yao Fang. 16:1886–1888. 2005.(In Chinese).
20	World Health Organization (WHO). global tuberculosis control report. 2010, http://reliefweb.int/sites/reliefweb.int/files/resour-ces/F530290AD0279399C12577D8003E9D65-Full_Report.pdf. Accessed April 28, 2014
21	Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 60:1650–1653. 2011.
22	Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 365:2155–2166. 2011.